Kuliya-Gwarzo, A, Ibegbulam OG, Mamman A, Raji AA, Akingbola TS, Mabayoje VO, Ocheni S, Tanko Y, Amusu OA, Akinyanju OO, Ndakotsu MA, Kassim DO, Arewa OP, Bolarinwa RAA, Olaniyi JA, Okocha CE, Akinola NO, Bamgbade OO, Adediran IA, Salawu L, Faluyi JO, Oyekunle AA, Okanny CC, Akanmu S, Halim DNK, Bazuaye GN, Enosolease ME, Nwauche CA, Ogbe OP, Wakama TT, Durosinmi MA.
2008.
The use of Imatinib mesylate (Glivec) in Nigerian patients with chronic myeloid leukemia.. Cellular Therapy and Transplantation. 1:10.3205/ctt-2008-en-000027.01., Number 2
AbstractObjectives: To assess response and toxicity to Imatinib mesylate (Glivec) in Nigerian Patients with chronic myeloid leukemia. Methods: From August 2003 to August 2007, 98 consecutive, consenting patients, 56 (57%) males and 42 (43%) females, median age 36 years (range, 11-65 years) diagnosed with CML, irrespective of disease phase received Imatinib at a dose of 300-600mg/day at the OAU Teaching Hospitals, Nigeria. Response to therapy was assessed by clinical, haematological and cytogenetic parameters. Blood counts were checked every two weeks in the first three months of therapy. Chromosome analysis was repeated sixth monthly. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR) were evaluated. Results: Complete haematologic remission was achieved in 64% and 83% of patients at one and three months, respectively. With a median follow-up of 25 months, the rates of CCR and MCR were 59% and 35% respectively. At 12 months of follow-up, OS and progression- free survival (PFS) were 96% and 91%, respectively. Achievement of CR at six months was associated with significantly better survival (p = 0.043).Conclusions: Compared to treatment outcome with conventional chemotherapy and alpha interferon, as previously used in Nigeria, the results obtained with this regimen has established Imatinib as the first-line treatment strategy in patients with CML, as it is in other populations, with minimal morbidity.
Komolafe, EO, Adeolu AA, Komolafe MA.
2007.
Treatment of cerebrospinal fluid shunting complications in a nigerian neurosurgery programme: Case illustrations and review, 2007. Pediatric Neurosurgery. 44(1)
AbstractBackground/Aims: For a century since the first cerebrospinal fluid (CSF) shunt surgery, ventriculoperitoneal (VP) shunt insertion for the treatment of hydrocephalus has routinely been performed. A lot of common and rare complications following this procedure have been reported in 24-47% of the cases. The aim of this paper was to present our experience with the treatment of hydrocephalus in our centre and highlight our management of two unusual complications with the available resources. Methods: Retrospective clinical review. Results: A total of 86 patients with hydrocephalus were seen in our unit. There were 52 males and 34 females (male:female ratio 3:2). The age of the patients ranged from 1 day to 68 years. The majority of the patients (92%) were below 5 years of age. Sixty-five patients had shunting procedures [VP shunt: 62 (95.4%); endoscopic third ventriculostomy: 3 (4.6%)]. Of the 62 patients with VP shunts, 16 (25.8%) had complications while 2 of the 3 patients with endoscopic third ventriculostomies had complications. The complications following the VP shunts were CSF shunt sepsis (n = 12; 19.4%), abdominal complications (n = 3; 4.8%), subdural haematoma (n = 2; 3.2%) and scalp necrosis in 1 patient. Conclusion: VP shunt procedures have come to stay and will remain with us despite recent advances such as endoscopic third ventriculostomy. Care should be taken to prevent all complications whether common or rare by paying particular attention to patient selection, shunt selection and surgical details. The adaptation of local technology and justified use of limited facilities and resources can go a long way in the management of both common and rare complications in developing nations. Copyright © 2008 S. Karger AG.
Komolafe, MA, Sanusi AA, Idowu AO, Balogun SA, Olorunmonteni OE, Adebowale AA, Fawale MB, Mosaku KS.
2021.
Sleep medicine in Africa: Past, present, and future, 2021. Journal of Clinical Sleep Medicine. 17(6)
AbstractInterest in sleep and sleep disorders in Africa dates back thousands of years, influenced by various cultural and religious beliefs. However, the practice of sleep medicine as a specialty has been inadequate compared to other regions of the world. The objective of this study was to explore the current status of sleep medicine in Africa vis-à-vis education, professional societies, and facilities, and to identify challenges of the specialty in the region. A literature search of major electronic databases (PubMed, Google Scholar) was done. This revealed that there is a high prevalence of sleep disorders in Africa and a significant association with epilepsy, human African trypanosomiasis, human immunodeficiency virus, and other diseases. There are 6 sleep societies in Africa located in 4 countries. Forty-one sleep laboratories were identified located in 4 countries. The challenges hindering development of sleep medicine in Africa include lack of awareness, poor funding, lack of facilities, and inadequate training.
Komolafe, MA, Olaogu MOB, Adebiyi AM, Obembe AO, Fawale MB, Adebowale AA.
2015.
Stroke risk factors among participants of a world stroke day awareness program in South-Western Nigeria, 2015. Nigerian Journal of Clinical Practice. 18(6)
AbstractIntroduction: Stroke is a major cause of death and disability in population across the world. Hypertension is the most common stroke risk factor globally as well as in the Nigerian population, however other modifiable risk factors such as obesity are becoming increasingly prevalent due to unhealthy diets and sedentary lifestyle. Materials and Methods: We screened 224 volunteers from Ile-Ife during the 2011 and 2012 world stroke day commemorative activities. Blood pressures (BP) were measured and body mass index (BMI) was determined from weight and height measurements. The data from 40 (18%) were incomplete and were excluded from further analysis. Results: The 184 subjects eligible for analysis comprised 85 males (46.2%) and 99 females (53.8%), with a male to female ratio of 0.85:1. Their ages ranged from 16 to 95 years (mean, 53 ± 16 years). 25% of the study population had stage 1 or 2 hypertension (mean systolic blood pressure: 127 ± 27 mmHg, mean diastolic blood pressure: 78 ± 16 mmHg), while 34.8% and 14.7% were overweight and obese, respectively (mean BMI: 25.8 ± 5.0 kg/m2). Conclusion: Stroke risk factors such as hypertension and obesity were common among the participants of the world stroke day awareness program in an urban area of Nigeria. Community screening and modification of these risk factors should be intensified in order to reduce stroke morbidity and mortality.
Komolafe, MA, Sunmonu TA, Afolabi OT, Komolafe EO, Fabusiwa FO, Groce N, Kett M, Disu JO, Ajiboye JK, Olaniyan SO.
2012.
The social and economic impacts of epilepsy on women in Nigeria, 2012. Epilepsy and Behavior. 24(1)
AbstractBackground: Persons with epilepsy in sub-Saharan Africa experience stigma and social marginalization. There is paucity of data on the social and economic impacts of epilepsy in these patients and in particular, groups like women. We sought to determine the social and economic impacts of epilepsy on Nigerian women and especially how it affects their treatment and outcomes. Methods: We carried out a cross-sectional survey of 63 women with epilepsy (WWE) and 69 controls matched for age, social status and site of care. A structured questionnaire was used to document information on demographic characteristics, education, employment status, economic status, health care use, personal safety and perceived stigma. The data were collated and analyzed with SPSS version 15. Results: Unemployment, fewer years of formal education, lower marriage rates and higher stigma scores were more frequent among WWE than controls. Physical and sexual abuse with transactional sex was also reported among WWE. We also noted poorer environmental and housing conditions and lower mean personal and household incomes among WWE compared to the control group. Conclusion: WWE in this sample from Nigeria have worse social and economic status when compared with women with other non-stigmatized chronic medical conditions. © 2011 Elsevier Inc.
Komolafe, MA, Fatusi OA, Alatise OI, Komolafe EO, Amusa YB, Adeolu AA, Durosinmi MA.
2009.
The role of human immunodeficiency virus infection in intranuclear facial paralysis, 2009. Journal of the National Medical Association. 101(4)
AbstractBackground: This study describes the pattern of idiopathic intranuclear facial palsy (facial neuropathy) and highlights the role of human immunodeficiency virus (HIVJ/AIDS in its occurrence and management. Patients and Methods: This study conducted in lle-lfe, Nigeria, assessed individuals with idiopathic facial neuropathy seen at the neurology; maxillofacial surgery; and ear, nose and throat outpatient clinics between 1994 and 2006. Results: Eighty-eight patients with idiopathic facial neuropathy were seen during the 13-year study period. Forty-six (52.3%) were males, and the age range was 15 to 76 years, with a median of 35.5 years and interquartile range of 24.5 to 54 years. The right side was affected in 59.1%, compared with 40.9% on the left side. Twenty-six patients (29.5%) were HIV positive at presentation: 16 males, 10 females; mean age for HIV-positive patients was 29.15 ± 8.12 years and 44.39 ± 18.48 years for HIV-negative patients. There was a significant relationship among the status of the patients and the severity at presentation (p =.035), treatment given (p =.019), and the occurrence of flu-like symptoms (p =.004). Conclusion: A high index of suspicion of seroconversion is essential in patients presenting with idiopathic facial neuropathy since it has implications for management. Serological testing for HIV, especially in patients at risk and those with history of recent flu-like symptoms, is recommended.